Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Neuroblastoma affects approximately 500 children a year in the United States. When the tumor
occurs in infants, it is frequently localized and responds well to therapy. Even disseminated
disease can be eradicated in about 75% of infants, and indeed may undergo spontaneous
remission. In older children, the prognosis is far worse, and 80% or more of those with
disseminated tumor can be expected to relapse within 3 years.
This study will utilize the concept of exploiting the immune system to eradicate
neuroblastoma. In tumors in which there is consistent expression of tumor specific antigens
as part of the malignant process, it may be possible to generate immune T-cells ex-vivo or
in-vivo by using the specific protein or peptide(s) derived therefrom and eradicate the
tumor. This study will evaluate the use of four to eight injections of IL-2 gene-transduced
autologous neuroblastoma cells to induce a local, polyclonal T-cell infiltrate as well as an
anti-tumor immune response.
Phase:
Phase 1
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
National Cancer Institute (NCI) Texas Children's Cancer Center